Intellia Therapeutics (NTLA) Cash & Equivalents (2015 - 2026)

Intellia Therapeutics (NTLA) has 12 years of Cash & Equivalents data on file, last reported at $134.7 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $134.7 million, up 6.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $134.7 million (up 6.16% YoY), and the FY2025 annual result was $155.5 million, down 17.82% from the prior year.
• Cash & Equivalents slipped to $134.7 million in Q1 2026 per NTLA's latest filing, from $155.5 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $523.5 million in Q4 2022 and troughed at $120.5 million in Q3 2024.
• A 5-year average of $187.4 million and a median of $156.2 million in 2025 frame the typical range for Cash & Equivalents.
• On a YoY basis, Cash & Equivalents climbed as much as 317.18% in 2022 and fell as far as 57.82% in 2022.
• A 5-year view of Cash & Equivalents shows it stood at $523.5 million in 2022, then tumbled by 56.69% to $226.7 million in 2023, then decreased by 16.57% to $189.2 million in 2024, then decreased by 17.82% to $155.5 million in 2025, then dropped by 13.36% to $134.7 million in 2026.
• Business Quant data shows NTLA's Cash & Equivalents at $134.7 million in Q1 2026, $155.5 million in Q4 2025, and $193.4 million in Q3 2025.